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Opinion statement
Radiation is established as one of the most powerful, highly effective treatments for
non-Hodgkin lymphoma (NHL). Unfortunately, in recent years the medical oncol-
ogy community has improperly underutilized radiotherapy (RT) in the management
of NHL. Replacing RT with longer chemotherapy and/or immunotherapy may not
necessarily be a good alternative approach and may lead to suboptimal outcome
and more toxicity, particularly in patients with localized disease. Some misconcep-
tions regarding the use of RT emanated from the ways RT has been utilized in the
past—as a single therapy and in high doses and large fields. Major developments
in imaging technology, radiation planning concepts, and RT precision and delivery
have been revolutionized RT for NHL over the past two decades. Modern proper
administration should result with very minimal acute or late side effects. Some
of the controversial issues of the use of RT borrowed from Hodgkin lymphoma,
such as risk of secondary tumors, are irrelevant to patients with NHL but cause
unnecessary patient and physician scare. Many lymphoma types are notoriously
sensitive to RT, especially the indolent types. When localized, like in most margin-
al zone lymphoma (MZL) and almost a third of follicular lymphomas (FL), RT is
potentially curative, even with low dose and small volumes. In more aggressive
lymphomas, RT often is an effective consolidation after chemotherapy in complete
or even incomplete responders. It also is an important component of salvage and
palliation. In older patients, RT is particularly valuable, because chemotherapy
tolerance and salvage options may be limited. The International Lymphoma
Radiation Oncology Group (ILROG) developed and published modern guidelines
for using RT in NHL, including FL. The guidelines emphasize the new concept
of RT field: involved site radiotherapy (ISRT). These modern ILROG principles and
several relevant studies that looked into the proper integration of RT in themanagement of
NHL patients are the focus of this manuscript.
Introduction
Ionizing radiation is a highly effective modality for
the treatment of most lymphomas. The dramatic ef-
fects of radiation alone in reducing large lesions
and even eliminating Hodgkin lymphoma (HL) le-
sions were reported more than 112 years ago, soon
after the discovery of x-rays by Wilhelm Conrad
Roentgen. Yet, during the first half of the 20th cen-
tury, when all lymphomas remained incurable, ra-
diat ion was used mostly for pal l iat ion and
responses where brief due to technical constraints
and/or poor methods of delivering radiation. As
x-ray technology improved in the 1940s and the
concept of irradiating beyond the involved area
was adopted, patients with early-stage HL and
non-Hodgkin lymphoma (NHL) could be cured
with radiation alone—the only effective curative
modality for lymphomas that was available until
the late 1960s.
Before the advent of effective chemotherapy, at-
tempts were made to cure NHL by maximizing the
use of radiation alone. Optimizing the selection of pa-
tients and tailoring the radiation fields was associated
with aggressive staging efforts that included using stag-
ing laparotomy for HL and even NHL. Moreover, the
dependency of RT as a single modality required wide
extension of the radiation field as well as raising the
dose to normal tissue tolerance levels. While this rad-
ical radiotherapy led to the cure of many patients, it
also was associated with late development of compli-
cations and increased the mortality of cured patients
beyond what is expected of the normal population.
This was the price of successfully pioneering radiation
therapy as a curative modality before the availability
of effective chemotherapy.
The emergence of more effective and less toxic che-
motherapy over the past three decades led to consider-
able changes in the use of RT in the management of
lymphomas. First, in several types of NHL, chemother-
apy has become the primary modality with radiother-
apy used for consolidation and reduction of relapse
risk. Yet, in some lymphomas, mostly early-stage,
low-grade lymphomas where chemotherapy is less ef-
fective, radiation alone remained the standard of care.
Radiation alone is currently the treatment of choice for
localized follicular lymphoma (FL) and marginal zone
lymphoma (MZL) lymphomas.
Localized stages of FL (I and contiguous II) occur in
approximately 22 % to 33 % of all cases [1, 2]. Some
of these early-stage patients may have a normal bone
marrow examination by morphology, but sensitive es-
says may detect a clonal population of B cells in the
blood and/or bone marrow. The clinical significance
of this finding in patients treated with local therapy
is still uncertain.
Early-stage patients present often with a median age
of 60 years, usually with a good performance status, no
systemic symptoms, and normal LDH. The disease is
likely to be confined to one anatomic region, often the
neck or inguinal area. Involvement of an extranodal site
is less common, only 25 % of patients [3].
Finally, radiotherapy is an excellent palliative mo-
dality that provides long-term local control and clini-
cal benefit even for lymphomas in advanced-stage,
such as follicular lymphoma, small lymphocytic lym-
phoma, MZL, and mantle cell lymphoma. These spe-
cific types of lymphoma are highly sensitive to
radiation and very low doses may be adequate for ex-
tended local control [4].
The rationale for using RT in follicular lymphoma
For patients with stage I or contiguous stage II follicular lymphoma RT alone
is well recognized, “preferred,” or the treatment of choice. [5] Several
centers reviewed the long-term outcome of RT alone and reported relapse-
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free survival in the range of 50 % at 10 years and approximately 40 % at
15 years; overall survival rates were 60-80 % and 35-45 %, respectively.
Median survival in some series was 19 years. Thus, RT is likely curative for a
significant number of patients with early-stage FL [2, 3].
The largest retrospective study of 6,568 patients with follicular lymphoma
stage I or II diagnosed between 1973 and 2004 was based on SEER data [6].
In 34 % of these patients, RT was used as the initial treatment. The group
receiving RT at the onset had higher rates of disease-specific survival at
5 years (90 vs. 81 %), 10 years (79 vs. 66 %), 15 years (68 vs. 57 %), and 20
(63 vs. 51 %) years. Overall survival also was improved for patients who
received initial radiation therapy. With RT, most of the lesions completely
regress and local relapse at an irradiated site is rare. Relapses usually occur
distant from the RT site and are rare after 10 years (1-11 %) [7, 8]. Risk
factors for relapse are age (960 years), abnormal LDH, and bulk.
These data support the notion that a substantial subset of patients with
limited-stage follicular lymphoma may be cured with radiotherapy alone.
Despite evidence supporting the use of radiation, the majority of patients
with stage I disease treated in the United States do not receive radiation
therapy [9]. The National LymphoCare Study (funded in part by Genentech
and Biogen) assembled patients with early-stage FL patients from several
institutions. The authors reported that despite NCCN guidelines
recommending RT alone as the preferred approach, only 23 % of the patients
received RT as their initial treatment [5]. Yet, an additional 20 % received RT
within 90 days after chemotherapy and/or rituximab either because of in-
adequate response/progression or possibly as part as planned combined
modality therapy. Surprisingly, 30 % of patients were “observed” possibly
based on very limited data of highly selected 43 patients from Stanford who
were not treated and had comparable outcome to the majority who received
RT. [10] Potentially misleading, in my opinion, is the second report from the
LymphoCare group of 206 patients that were rigorously staged to have only
one site of disease and of whom selectively only 27 % received RT, 17 % were
observed, 13 % had RT and another systemic treatment, 28 % had rituximab
and chemotherapy, and 12 % had rituximab alone [11]. At a median follow-
up of 5 years, no differences in progression-free survival (PFS) between the
different treatments selected for these patients. The retrospective nature and
almost certain selection bias for treatment should be highlighted before
making any conclusions on treatment choices from this small study.
Interestingly, the study also compared patients that were rigorously staged to
those that were considered stage I without appropriate staging. The rigor-
ously staged patients had significantly better PFS compared with those that
have not been fully staged, even after adjustment to patient, disease, and
treatment factors.
Clearly, the definition of stage I have changed over time and stage migra-
tion phenomena are relevant when discussing results of RT alone from
older series. The original series probably included of unknown fraction of
patients with more advanced stages and thus the relapse rate with localized
therapy is expected to be superior for current properly staged patients. One
caveat, however, is that older RT fields were significantly larger (and thus
more toxic) than today but could have controlled more nodal sites that
could potentially still relapse with today’s minimal RT.
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Another issue that has not been addressed as yet in early-stage FL is
the effect of treatment on the risk of transformation into aggressive lym-
phoma. It is logical to expect that patients whose localized disease has been
decimated by RT are less likely to transform. This question has not been
addressed yet by any study. Yet, it remains of concern that in the Stanford
retrospective follow-up of 43 patients with stage I-II FL that were selected to
no initial treatment, 4 patients have transformed into higher-grade
lymphoma [10].
Lower RT dose for indolent lymphomas
The indolent lymphomas (FL, MZL, CLL/SLL) as well as mantle cell lym-
phoma (MCL) are inquisitively radiosensitive. Yet, in the past, many clini-
cians used radiation doses in the range of 36-45 Gy to treat all types of
lymphoma based on some very old, questionable, dose-response studies
[12]. More recently, an important randomized study from the United
Kingdom compared the former standard dose of 40-45 Gy to 24 Gy in 361
involved sites of patients with indolent lymphomas (mostly FL and MZL in
early stages) [13•]. At a median follow-up of 5.6 years, there was no differ-
ence in overall response (93 %/92 %) between the standard and lower dose
arms. There was no difference in the rate of within radiation field progres-
sion, progression-free survival, or overall survival. Based on this seminal
study, the RT dose recommended for most cases of localized FL is 24 Gy
[5, 14•]. Exceptions that may suggest the employment a higher dose (30-
36 Gy) are bulky disease 95 cm and grade IIIA pathology. For the relatively
rare nodal MZL behave clinically and are managed according to stage like FL,
we also recommend ISRT of 24-30 Gy. The more common localized
extranodal MZL (MALT lymphomas) also are very sensitive to RT and should
be managed in the same low range of 24-30 Gy (see NCCN Guidelines [5]).
During the past 20 years, very low doses or RT of only 2 Gy X2 (known in RT
jargon as “boom-boom”) were shown to be highly effective when used for
palliation of advanced-stage, relapsing, or even post multiple chemotherapy
refractory patients with indolent lymphomas and MCL [15]. Amazingly, in
many cases this innocent RT dose resulted in complete local lasting responses.
The rewarding “boom-boom” experience with a total dose of only 4 Gy led
to a second UK randomized study called FORT. [16•] It was designed as
noninferiority study and the primary question for analysis was time to local
progression. A total of 614 sites in 548 patients with FL (and some with
MZL) were prospectively randomized to receive RT of either the newly
established dose of 24 Gy or the very low dose of 4 Gy. In 60 % the intent of
RT was considered as palliative and in 40 % as curative.
The results have been reported recently and clearly showed that 4 Gy was
inferior to 24 Gy in terms of time to local progression (hazard ratio of 3.4; 95
confidence interval [CI] 2.09-5.55, pG0.0001). Median follow-up was
26 months, with a range that extended to 75 months. The failure to dem-
onstrate noninferiority of the lower dose is particularly important in the
curative setting of previously untreated localized disease. The difference for
the curative intent subgroup also was significantly better for the higher dose.
Thus, 24 Gy remains the standard dose for curative treatment of localized
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disease until a lower dose (that is in between than 4 Gy and 24 Gy) is ex-
plored properly. In this large study, grade 3 acute or late side effects were rare
(4 Gy: acute 1.3 %, late 1.3 %; 24 Gy: acute 2.8 %, late 1.4 %). There was
only grade 4 event of myelosuppression.
Although the dose of 24 Gy also yielded better results for local control
duration in the palliative setting, the results with 4 Gy were quite impres-
sive with almost 50 % of patients achieving a complete response and another
32 % having regression of more that 30 % of their disease [17•]. Thus, 4 Gy
remains an excellent option for many patients in the palliative and relapse/
setting. It often, in my opinion, serves the patient better that another round
of systemic treatment or participation in phase I studies and should be
practiced more frequently. Obviously “boom-boom” may be repeated mul-
tiple times; multiple sites or one large field may be treated at the same time
and all that is required are only two visits to the RT facility.
Modern RT (and smaller) field design for patients with follicular
lymphoma: The involved site radiotherapy (ISRT) approach
The early RT studies used very large fields that often included irradiation of all
involved and uninvolved lymph nodes and even the spleen; the field was called
total lymphoid irradiation (TLI). This approachwas developed at Stanford at the
1960s and resembled the approach toRT ofHodgkin lymphoma at the time. For
the last three decades, it has been replaced by more limited fields of radiation
that restricted the treatment to the lymph node groups on only one side of the
diaphragm, such as the mantle field for involvement of the upper body lymph
nodes and Inverted Y large field for the lower part. Although radiation that in-
clude fields on both side of the diaphragms resulted in a better freedom of re-
lapse in the era of primitive staging, there was no difference in overall survival
and salvage options were limited by irradiation to full dose to a large part of the
bone marrow space [18].
Radiation fields later included only the regional or the involved fields; adja-
cent lymph node areas to the involved node/nodes were irradiated and field
borders were determined by anatomical landmarks, often skeletal structure that
could easily be identified by fluoroscopy technique used to plan the treatment.
With the advent of CT simulation often with data from FDG-PET-CT,
localization of involved or suspicious lymph nodes was more precise and thus
easier to target. Safer reduction of the RT volume and avoidance of normal
structures as well more sophisticated treatment planning programs, such as
three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated
intensity radiotherapy (IMRT) have become available in most centers.
A study from Vancouver looked retrospectively at patients that with lim-
ited-stage follicular lymphoma treated either to the involved region or to a
smaller field limited to the involved site. [8] At a median follow-up of
7.5 years, both the larger and the smaller fields yielded excellent local con-
trol. Only 1 % of patients who were treated with the smaller “involved node”
approach relapsed in adjacent regional nodes and there was no difference
with respect to distant failure between the two groups (involved site-32 %,
Regional RT-38 %).
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To guide and harmonize field concepts and design, the International
Lymphoma Radiation Oncology developed and recently published RT guide-
lines for nodal based NHL, including follicular lymphomas. [14•] These
guidelines for volume and dose have been adopted by the NCCN and provide
the basis for the current approach for using RT in lymphoma patients [5].
The recommended field contains only the involved site, is based on im-
aging information, and is influenced by clinical consideration, such as the
availability of high-quality imaging before intervention that could have af-
fected the information, such as excision or systemic treatment, on the im-
aging at the time of simulation, the histology and potential presence of
microscopic disease, particularly if RT is the only modality that is used for
curative purposes, as often is the case in localized FL.
The radiation oncologist is expected to exercises clinical judgment based
on these principles to determine the CTV (clinical target volume) and em-
ploys ICRU principles to determine the PTV (planning treatment volume).
The end result of using the ISRT concept often is a RT field that is signif-
icantly smaller than the regional and involved-field practiced in the past. Yet,
it is more generous than the very strict involved-node RT (INRT) that was
designed for Hodgkin lymphoma patients that have optimal imaging data
prior to any intervention that can be integrated into the postchemotherapy
planning CT [19].
Summary
New information based on randomized studies allowed a significant reduc-
tion in RT dose to 24 Gy for potentially curative cases. Increasing experience
that supports the benefit from very small dose of 4 Gy for palliative or
heavily pretreated, relapsed, or refractory patients. The lower dose approach
made radiation safer and easier to administer to many patients in various
stages of FL. Most side effects concerns of the past, such as dryness of the
mouth or other organ malfunction, are irrelevant with this low-dose small
volume approach. Limiting and smartly determining the RT field according
to ILROG guidelines allows using RT with a better therapeutic ratio than in
the past. The very large studies that documented that RT in NHL patients do
not have an increased risk of second malignancies also are reassuring.
Radiation should remain an important modality for the best care of FL pa-
tients. Oncologists should make the best use of its availability, particularly in
patients with indolent lymphomas.
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